ColdZyme Distribution Deal for Iraq and Jordan
Sweden's Enzymatica AB has partnered with MedonyX for the exclusive distribution of its ColdZyme mouth spray in Iraq and Jordan. This long-term agreement aims to expand the product's market reach across key Middle Eastern healthcare sectors.
Enzymatica AB has successfully secured a long-term exclusive distribution agreement with MedonyX to bring its flagship ColdZyme mouth spray to Iraq and Jordan. MedonyX is backed by MMDS, a prominent Jordanian healthcare and market-access firm with deep regional expertise. The partnership covers the comprehensive registration, marketing, sales, and distribution processes necessary for a successful regional rollout. Both companies anticipate a strong market entry as consumer demand for preventative healthcare solutions remains robust in the Middle East. This strategic expansion represents a milestone for Enzymatica as it seeks to scale its international footprint beyond traditional European markets. Financial terms of the agreement were not disclosed, but initial product launches are already slated for both territories.
Miễn trừ trách nhiệm về phân tích AI
Phân tích tác động tài sản do AI tạo ra và chỉ mang tính tham khảo. Đây không phải lời khuyên tài chính. Hãy luôn tự nghiên cứu trước khi đưa ra quyết định đầu tư.
Thảo luận